Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR1H4 | Q96RI1 | 3/20 | 0.67 |
| ▸ | PARP15 | Q460N3 | 2/20 | 0.55 |
| ▸ | PARP10 | Q53GL7 | 2/20 | 0.55 |
| ▸ | KAT6A | Q92794 | 1/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.54 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.54 |
| ▸ | HPGD | P15428 | 1/20 | 0.53 |
| ▸ | RAB9A | P51151 | 1/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.53 |
| ▸ | SIRT2 | Q8IXJ6 | 1/20 | 0.52 |
| ▸ | KMO | O15229 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12420668 | 1.00 | NR1H4 (0.67) | NR1H4PARP15PARP10KAT6AKMT2A | |
| SCHEMBL12420676 | 1.00 | NR1H4 (0.67) | NR1H4PARP15PARP10KAT6AKMT2A | |
| SCHEMBL30575482 | 1.00 | NR1H4 (0.67) | NR1H4PARP15PARP10KAT6AKMT2A | |
| SCHEMBL30575478 | 0.98 | NR1H4 (0.68) | NR1H4PARP15PARP10KAT6AKMT2A | |
| SCHEMBL931299 | 0.98 | NR1H4 (0.68) | NR1H4PARP15PARP10KAT6AKMT2A | |
| SCHEMBL31661845 | 0.95 | NR1H4 (0.68) | NR1H4PARP15PARP10KAT6AKMT2A | |
| SCHEMBL3069471 | 0.95 | NR1H4 (0.68) | NR1H4PARP15PARP10KAT6AKMT2A | |
| SCHEMBL3060401 | 0.92 | NR1H4 (0.76) | NR1H4PARP15PARP10KMT2ANR4A2 | |
| SCHEMBL30281276 | 0.92 | NR1H4 (0.76) | NR1H4PARP15PARP10KMT2ANR4A2 | |
| SCHEMBL7439527 | 0.87 | PARP10 (0.69) | NR1H4PARP15PARP10KAT6ASIRT2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 49 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170189443-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF DISEASES AND CONDITIONS EMPLOYING ORAL ADMINISTRATION OF SODIUM PENTOSAN POLYSULFATE AND OTHER PENTOSAN POLYSULFATE SALTS | PLATINUM MONTAUR LIFE SCIENCES, LLC AND AS AGENT (KY) | 2017-07-06 | — | — | US | claimed |
| EP-3110427-A1 | COMPOSITIONS OF PENTOSAN POLYSULFATE SALTS FOR ORAL ADMINISTRATION AND METHODS OF USE | Urigen Pharmaceuticals, Inc. (US) | 2017-01-04 | — | — | EP | claimed |
| WO-2015127416-A1 | COMPOSITIONS OF PENTOSAN POLYSULFATE SALTS FOR ORAL ADMINISTRATION AND METHODS OF USE | URIGEN PHARMACEUTICALS, INC. (US) | 2015-08-27 | — | — | WO | claimed |
| US-20230270700-A1 | PHARMACOLOGY OF VISUAL CYCLE MODULATORS | ACUCELA INC. | 2023-08-31 | — | — | US | disclosed |
| CN-112812077-B | Benzamide compound, preparation method thereof, pharmaceutical composition and application | 中国科学院上海药物研究所 | 2023-08-22 | — | — | CN | disclosed |
| EP-2448569-B1 | PHARMACOLOGY OF VISUAL CYCLE MODULATORS | ACUCELA INC (US) | 2021-10-27 | — | — | EP | disclosed |
| CN-112812077-A | Benzamide compound and preparation method, pharmaceutical composition and application thereof | 中国科学院上海药物研究所 | 2021-05-18 | — | — | CN | disclosed |
| US-20200188336-A1 | PHARMACOLOGY OF VISUAL CYCLE MODULATORS | ACUCELA INC. | 2020-06-18 | — | — | US | disclosed |
| US-10471027-B2 | Pharmacology of visual cycle modulators | ACUCELA, INC. (US) | 2019-11-12 | — | — | US | disclosed |
| EP-2150526-B1 | N-ADAMANTYL BENZAMIDES AS INHIBITORS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE | VTV THERAPEUTICS LLC (US) | 2017-09-20 | — | — | EP | disclosed |
| US-20170189443-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF DISEASES AND CONDITIONS EMPLOYING ORAL ADMINISTRATION OF SODIUM PENTOSAN POLYSULFATE AND OTHER PENTOSAN POLYSULFATE SALTS | PLATINUM MONTAUR LIFE SCIENCES, LLC AND AS AGENT (KY) | 2017-07-06 | — | — | US | disclosed |
| WO-2008101240-A1 | COMPOUNDS HAVING A CYCLIC MOIETY AND COMPOSITIONS FOR DELIVERING ACTIVE AGENTS | EMISPHERE TECHNOLOGIES, INC. (US) | 2008-08-21 | — | — | WO | disclosed |
| WO-2008101240-A1 | COMPOUNDS HAVING A CYCLIC MOIETY AND COMPOSITIONS FOR DELIVERING ACTIVE AGENTS | EMISPHERE TECHNOLOGIES, INC. (US) | 2008-08-21 | — | — | WO | disclosed |
| US-20030191323-A1 | Hypoglycemic agent | AJINOMOTO CO., INC. (JP) | 2003-10-09 | — | — | US | disclosed |
| US-20030162818-A1 | Acylsulfonamide derivative | AJINOMOTO CO. INC. (JP) | 2003-08-28 | — | — | US | disclosed |
| US-6555584-B1 | Acetyl-coa carboxylase inhibitors | AJINOMOTO CO., INC. (JP) | 2003-04-29 | — | — | US | disclosed |
| EP-1300142-A1 | HYPOGLYCEMICS | Ajinomoto Co., Inc. (JP) | 2003-04-09 | — | — | EP | disclosed |
| EP-0579223-B1 | Carboxylic acid derivatives having 5 alpha-reductase inhibitory activity | MITSUBISHI CHEM CORP (JP) | 1996-10-09 | — | — | EP | disclosed |
| US-5385917-A | Treating androgen dependent diseases | MITSUBISHI KASEI CORPORATION (JP) | 1995-01-31 | — | — | US | disclosed |
| EP-0579223-A1 | Carboxylic acid derivatives having 5 alpha-reductase inhibitory activity | Mitsubishi Chemical Corporation (JP) | 1994-01-19 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230270700-A1 | PHARMACOLOGY OF VISUAL CYCLE MODULATORS | NR2E3, ALDH1A2, RARB | NR1H4 22/4885PARP15 2590/4885PARP10 1642/4885 |
| US-20030162818-A1 | Acylsulfonamide derivative | ACSS2, ACACA, FASN | NR1H4 1199/4885PARP15 4507/4885PARP10 3779/4885 |
| US-20200188336-A1 | PHARMACOLOGY OF VISUAL CYCLE MODULATORS | NR2E3, ALDH1A2, RARB | NR1H4 22/4885PARP15 2590/4885PARP10 1642/4885 |
| US-10471027-B2 | Pharmacology of visual cycle modulators | ALDH1A2, PDE6C, NR2E3 | NR1H4 304/4885PARP15 2170/4885PARP10 1058/4885 |
| US-20030191323-A1 | Hypoglycemic agent | GPR119, IAPP, SLC5A2 | NR1H4 1277/4885PARP15 2362/4885PARP10 2886/4885 |
| US-20170189443-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF DISEASES AND CONDITIONS EMPLOYING ORAL ADMINISTRATION OF SODIUM PENTOSAN POLYSULFATE AND OTHER PENTOSAN POLYSULFATE SALTS | SI, SLC20A1, SLC20A2 | NR1H4 1587/4885PARP15 4831/4885PARP10 4743/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.